Alejandro A Gru1, Carlos E Bacchi2, Melissa Pulitzer3, Govind Bhagat4, Werner Kempf5,6, Alistair Robson7, Jose A Plaza8, Laura Pincus9, Shyam Raghavan1, Mina Xu10, Tiago Vencato da Silva2, Andrea L Salavaggione1, Antonio Subtil11, Maxime Battistella12. 1. Department of Pathology, University of Virginia, Charlottesville, Virginia, USA. 2. Lab Bacchi, Botucatu, SP, Brazil. 3. Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. 4. Department of Pathology, Columbia University, New York, New York, USA. 5. Kempf und Pfaltz Histologische Diagnostik, Zurich, Switzerland. 6. Department of Dermatology, University Hospital Zurich, Zurich, Switzerland. 7. Institute of Oncology, Lisbon, Portugal and LDPath London, London, UK. 8. Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA. 9. Department of Dermatology, University of California San Francisco, San Francisco, California, USA. 10. Department of Pathology, Yale University, New Haven, Connecticut, USA. 11. Department of Pathology, Royal Jubilee Hospital, Victoria, British Columbia, Canada. 12. Pathology Department, Université de Paris, Hôpital Saint-Louis, Paris, France.
Abstract
BACKGROUND: Cutaneous involvement by classic Hodgkin lymphoma (CHL) is an extraordinarily rare phenomenon in the current era. To date, no single large case series of cutaneous involvement by Hodgkin lymphoma has ever been reported in the literature. METHODS: A comprehensive search for cases designated "skin" and "Hodgkin" was performed at different institutions between 1990 and 2020. Twenty-five cases were identified, and each case was independently reviewed by at least three board-certified dermatopathologists and/or hematopathologists. RESULTS: All cases represented examples of systemic CHL with secondary skin dissemination. A single lesion, usually a tumor, nodule or infiltrative plaque was observed in 56% of cases and multiple lesions were present in 28% of cases. Most patients (86%-12/14) had a diagnosis of stage IV disease at first diagnosis. The interval between the clinical (first) diagnosis of HL and the development of skin lesions ranged between 6 and 108 months (average 33.75 months). Comprehensive histopathologic evaluation of these cases (at the initial diagnosis) revealed a diagnosis of classic HL not otherwise specified (NOS) in 60% of cases (15/25), nodular sclerosis type in 24% (6/25), mixed cellularity in 12% (3/25), and lymphocyte depleted in 4% (1/25). CONCLUSIONS: We provide documentation of a large series of CHL with secondary skin involvement in association with CHL with additional clinical, morphologic, and immunophenotypic features.
BACKGROUND: Cutaneous involvement by classic Hodgkin lymphoma (CHL) is an extraordinarily rare phenomenon in the current era. To date, no single large case series of cutaneous involvement by Hodgkin lymphoma has ever been reported in the literature. METHODS: A comprehensive search for cases designated "skin" and "Hodgkin" was performed at different institutions between 1990 and 2020. Twenty-five cases were identified, and each case was independently reviewed by at least three board-certified dermatopathologists and/or hematopathologists. RESULTS: All cases represented examples of systemic CHL with secondary skin dissemination. A single lesion, usually a tumor, nodule or infiltrative plaque was observed in 56% of cases and multiple lesions were present in 28% of cases. Most patients (86%-12/14) had a diagnosis of stage IV disease at first diagnosis. The interval between the clinical (first) diagnosis of HL and the development of skin lesions ranged between 6 and 108 months (average 33.75 months). Comprehensive histopathologic evaluation of these cases (at the initial diagnosis) revealed a diagnosis of classic HL not otherwise specified (NOS) in 60% of cases (15/25), nodular sclerosis type in 24% (6/25), mixed cellularity in 12% (3/25), and lymphocyte depleted in 4% (1/25). CONCLUSIONS: We provide documentation of a large series of CHL with secondary skin involvement in association with CHL with additional clinical, morphologic, and immunophenotypic features.
Authors: Dennis P O'Malley; Ahmet Dogan; Yuri Fedoriw; L Jeffrey Medeiros; Chi Young Ok; Mohamed E Salama Journal: Ann Diagn Pathol Date: 2019-02-06 Impact factor: 2.090
Authors: Jorge J Castillo; Brady E Beltran; Roberto N Miranda; Ken H Young; Julio C Chavez; Eduardo M Sotomayor Journal: Am J Hematol Date: 2016-05 Impact factor: 10.047